SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recent partnership with Semtech for AI and cloud network optical engines, sparking optimism about potential collaborations with major Semtech customers like Apple, Amazon, and Intel. The community is discussing the high trading volume and potential for a significant breakout, with some anticipating a short squeeze and long-term growth in the AI connectivity sector. Investors are also excited by the large 2027 call option volume, possibly indicating a large long term position is being built.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors discuss its AI cloud services and potential for significant growth in the AI data center market. Community members are highlighting the company's multi-year contracts, revenue projections, and strategic shift from Bitcoin mining to AI infrastructure. Some analysts have given IREN a high price target, contributing to the positive sentiment.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto (GLTO) is experiencing significant volatility, driven by a high short interest and low float, leading to a battle between bulls anticipating a short squeeze and bears predicting a crash. The community is actively debating potential price targets and whether it can emulate similar runs seen in other stocks. This action is occurring without any specific news catalyst, contributing to the speculative nature of the trading activity.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NuCana ($NCNA) is trending due to renewed interest in its low float and upcoming data presentation at the ESMO Congress in October, sparking speculation of a potential squeeze. The community is drawing comparisons to other low-float runners and highlighting the company's strong cash runway into 2029. Some investors are also pointing to a recently published research article as a potential catalyst.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision of natural wellness and plant-based healing, contrasting with traditional pharmaceuticals. Community members are sharing links to the Weedcoin website and highlighting its connection to cannabis culture. The coin aims to promote accessibility and normalize natural medicine.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

Trilogy Metals is trending following news of a significant U.S. government investment, sparking discussions of a potential short squeeze and future double-digit prices. The community is weighing the implications of government involvement and potential catalysts. This activity occurs amid a broader focus on securing domestic mineral resources.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as chatter increases around its merger with quantum computing company Infleqtion. The community highlights Infleqtion's existing contracts, partnership with NVIDIA, and potential for growth compared to sector peers like $IONQ and $RGTI. Some investors believe $CCCX is currently undervalued and presents a compelling entry point into the quantum computing space.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is surging amid speculation of a partnership with Tesla, fueled by a teaser video and social media buzz. The community is actively discussing potential price targets and short squeeze opportunities, while also weighing the risks of the rumors being unfounded. Broader interest in the eVTOL sector and Archer's existing partnerships are also contributing to the conversation.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amidst community discussions about a potential new, more affordable Model Y, with debates focusing on its impact on existing Tesla owners and competition within the EV market; some are skeptical, while others anticipate a positive effect on sales volume and market share, especially as the new models offset the end of US tax incentives.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid discussions around its AI initiatives, particularly the Gemini model, and its potential impact on competition with companies like OpenAI. Community members are weighing the stock's valuation and growth prospects, with some pointing to its dominance in search and other areas. Additionally, developments in its Waymo robotaxi service and partnerships in the AI infrastructure space are sparking interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evaxion A/S (EVAX) said on Thursday that it has out-licensed its vaccine candidate EVX-B3 to Merck (MRK), sending shares of the company rallying 42% in the pre-market session.Evaxion will receive a cash payment of $7.5 million in addition to future milestone payments of up to $592 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://evaxion.ai/investors/press-releases/?press_release_id=10586">said</a>. It will also be eligible for royalties on net sales.The cash payment will extend Evaxion’s cash runway to the first half of 2027, it said. Cash at hand will be invested in operating and developing the business, it added.The out-licensing is part of the option and license agreement between the two companies in September 2024. Merck will now be wholly responsible for the further development of the EVX-B3 vaccine, which is in preclinical development.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EVAX">EVAX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.EVX-B3 was discovered and developed in a collaboration between Evaxion and Merck. It aims to address a serious global medical issue for which no vaccines are currently available, Evaxion said, without naming the condition.Merck retains an option in a second vaccine candidate called EVX-B2. It is a preclinical vaccine candidate against Gonorrhea, and a decision on potential licensing is expected in the first half of 2026. Were Merck to exercise the option, Evaxion will receive a cash payment of $2.5 million and will be eligible for milestone payments of up $592 million in addition to royalties on sales.EVAX stock is down 22% this year and approximately 77% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened

The company said it will receive a cash payment of $7.5 million, in addition to future milestone payments of up to $592 million.

Equity

The company said it will receive a cash payment of $7.5 million, in addition to future milestone payments of up to $592 million.


Evaxion Biotech A/S (NASDAQ:EVAX) Stock Rating Upgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Evaxion Biotech A/S (NASDAQ:EVAX - Free Report) from a neutral rating to a buy rating in a report published on Tuesday, Marketbeat.com reports. The firm...

Q4 2023 Evaxion Biotech A/S Earnings Call (Danish) Transcript

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...

Evaxion Biotech Announces Upcoming Annual Meeting

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has announced its annual general meeting scheduled for April 16, 2024, e...

Evaxion Announces Business Update and Full Year 2023 Financial Results

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology  Platform

The proprietary AI-Immunology platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology outcompetes...

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ( Evaxion or the Company ), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion Biotech A/S Expected to Post FY2023 Earnings of ($6.90) Per Share (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX  Free Report)  Equities researchers at HC Wainwright issued their FY2023 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued...

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

EVAX Evaxion Biotech

Feed

News

Sentiment

Fundamentals

Info

Latest EVAX News